Public record

Ozempic: the public record

1 table from US federal sources. Latest data date: 2025.

Each table is computed from the named federal dataset as of its data date; the method is under each one.

Medicaid

Medicaid prescriptions for Ozempic by state

State Medicaid programmes paid for 3,695,001 Ozempic prescriptions in 2025, with $3.75B reimbursed before rebates. California reported the most (915,071), followed by New York (464,371) and Pennsylvania (234,731); 52 states and territories reported any.

Medicaid prescriptions for Ozempic by state: the figures
MeasureValueNote
Prescriptions paid by Medicaid, 20253,695,001
Total reimbursed before rebates, 2025$3.75B
States and territories reporting52with at least one count CMS did not suppress
California915,071 prescriptions$888.9M reimbursed
New York464,371 prescriptions$546.0M reimbursed
Pennsylvania234,731 prescriptions$240.5M reimbursed
Kentucky176,529 prescriptions$151.5M reimbursed
North Carolina156,494 prescriptions$175.1M reimbursed

Source: CMS, Medicaid State Drug Utilization Data 2025, data as of 2025

How this was calculated

Matched each Medicaid product code to the FDA NDC Directory by labeler and product code, kept finished single-ingredient products, then summed prescriptions and reimbursement by state. National roll-up and suppressed rows dropped.

Scope: Ozempic only (brand-name semaglutide), fee-for-service and managed care, 2025

Counts under 11 are suppressed by CMS and left out, so totals are a floor. Amounts are before rebates. Differences between states reflect programme size and coverage rules. Compounded products are not included.

Download the data (CSV)

Articles on Ozempic